TITLE

Late onset tuberculosis infection in patients receiving anti-TNFα therapy

AUTHOR(S)
Mongey, A.-B.; Doran, J.P.; Kleinerova, J.; FitzGerald, O.; McDonnell, T.J.
PUB. DATE
January 2014
SOURCE
QJM: An International Journal of Medicine;Jan2014, Vol. 107 Issue 1, p69
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
93398906

 

Related Articles

  • TNFα Inhibitors in the Treatment of Psoriasis and Psoriatic Arthritis. Tobin, Anne-Marie; Kirby, Brian // BioDrugs;2005, Vol. 19 Issue 1, p47 

    Psoriasis is a chronic inflammatory skin disease that can lead to significant physical and psychologic distress for patients. Psoriatic arthritis (PsA), originally thought to be quite a mild disorder, is now recognized as a progressive and destructive arthritis. To date, therapies for both these...

  • Analiza skutecznoÅ›ci i bezpieczeÅ„stwa terapii inhibitorami TNF-a Å‚uszczycy zwyczajnej i Å‚uszczycowego zapalenia stawów. Lesiak, Aleksandra; Olejniczak, Irmina; Sysa-Jędrzejowska, Anna; Zalewska-Janowska, Anna; Narbutt, Joanna // Clinical Dermatology / Dermatologia Kliniczna;2010, Vol. 12 Issue 4, p245 

    Introduction: Psoriasis is a chronic, inflammatory skin disease, affecting 2% of population. Therapeutic regiments include local and systemic agents. The latest method of treatment are TNF-α inhibitors. TNF-α plays an important role in psoriasis pathogenesis. Currently there are three...

  • Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Saad, Amr A.; Ashcroft, Darren M.; Watson, Kath D.; Symmons, Deborah P. M.; Noyce, Peter R.; Hyrich, Kimme L. // Rheumatology;Apr2010, Vol. 49 Issue 4, p697 

    Objectives. To evaluate the risk–benefit profile of anti-TNF therapies in PsA and to study the predictors of treatment response and disease remission [disease activity score (DAS)-28 < 2.6].

  • Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. Parker, Ben // Current Medical Literature: Dermatology;2013, Vol. 18 Issue 3, p74 

    A review of the article "Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study," which appeared in the periodical "Ann Rheum Dis" in 2013 is presented.

  • Adalimumab/etanercept/infliximab.  // Reactions Weekly;7/11/2009, Issue 1260, p5 

    The article describes six cases of late-onset tuberculosis in patients receiving adalimumab, etanercept or infliximab for either rheumatoid arthritis or psoriatic arthritis. All of the patients were diagnosed with tuberculosis, confirmed by bacterial culture, after treatment with tumour necrosis...

  • The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection. Atteno, Mariangela; Costa, Luisa; Matarese, Alessandro; Caso, Francesco; Puente, Antonio; Cantarini, Luca; Bocchino, Maria; Sanduzzi, Alessandro; Scarpa, Raffaele // Clinical Rheumatology;Apr2014, Vol. 33 Issue 4, p543 

    Psoriatic arthritis (PsA) is an inflammatory arthropathy associated with skin and/or nail psoriasis. TNF-α is an essential cytokine for the host defense, and its depletion by treatment may facilitate the risk of infections or their reactivation. The aim of this study was to evaluate the...

  • Different Transcriptional Activity and In Vitro TNF-α Production in Psoriasis Patients Carrying the TNF-α 238A Promoter Polymorphism. Kaluza, Wiebke; Reuss, Esther; Grossmann, Sabine; Hug, Rosula; Schopf, Rudolph E.; Galle, Peter R.; Maerker-Hermann, Elisabeth; Hoehler, Thomas // Journal of Investigative Dermatology;Jun2000, Vol. 114 Issue 6, p1180 

    SummaryGenes encoded on chromosome 6 within the major histocompatibility complex region are thought to play an important role in the pathogenesis of psoriasis. A potential candidate gene is tumor necrosis factor α. The tumor necrosis factor α promoter contains several polymorphisms...

  • Reply. Höhler, Thomas // Journal of Investigative Dermatology;Dec2000, Vol. 115 Issue 6, p1163 

    Discusses the association of psoriatic arthritis and psoriasis transition polymorphism in the tumor necrosis factor (TNF)-alpha promoter region. Influence of the polymorphism on the transcription of the TNF-alpha gene; Decrease in the production of TNF-alpha by T lymphocytes; Contribution of...

  • Anti-Tumor Necrosis Factor-α Treatment with Infliximab for Disseminated Granuloma Annulare. Murdaca, Giuseppe; Colombo, Barbara Maria; Barabino, Gianfranco; Caiti, Matteo; Cagnati, Paola; Puppo, Francesco // American Journal of Clinical Dermatology;2010, Vol. 11 Issue 6, p437 

    Granuloma annulare (GA) is a chronic inflammatory disease of unknown etiology characterized by the development of plaques preferentially localized to the distal extremities. Spontaneous remission and relapses are quite common and the course of GA is not easy to predict. Moreover, most...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics